CD19 and non-Hodgkin lymphoma: SB successfully entered the clinical stage in 2011 with two clinical trials as the first nonviral vector being used to generate CD19-specific CAR-T cells for adjuvant immunotherapy targeting minimal residual disease of non-Hodgkin's lymphoma (NHL) and ALL following hematopoietic stem cell transplantation (HSCT).37 Here, SB was successfully used to shuttle a second-generation, CD19-specific CAR cassette in a classic double-plasmid delivery setting.38